Head to head
Metformin against Pioglitazone
Two old oral diabetes drugs with unusual afterlives in the longevity literature. Pioglitazone has real cardiovascular outcome data and a boxed warning for heart failure; in the 2026 mouse cohort it was the only compound that shortened female lifespan in the analysis that survived removing an outlier site.
Column A
MetforminMetformin hydrochloride (biguanide)
The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Column B
PioglitazonePioglitazone (Actos), thiazolidinedione PPAR-gamma agonist
An approved diabetes drug with real cardiovascular outcome data in people, and the only compound in the 2026 mouse cohort that shortened female lifespan in the analysis that survived removing an outlier site.
Side by side, on the facts we can check
| Attribute | Metformin | Pioglitazone |
|---|---|---|
| Category | Longevity | Metabolic |
| FDA status | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. | FDA-approved as Actos for type 2 diabetes. Carries a boxed warning for congestive heart failure. Not approved for any ageing or longevity indication. |
| Half-life | 4 to 9 hours (plasma), longer in erythrocytes | Three to seven hours for the parent compound, with active metabolites extending to roughly 16 to 24 hours, which supports once-daily dosing. |
| Molecular weight | 129.2 Da (165.6 Da as hydrochloride) | 356.4 Da. A small molecule, not a peptide. |
| Mechanism | Inhibits mitochondrial complex I and activates AMPK, reducing hepatic glucose output and improving insulin sensitivity. The AMPK account is incomplete and the relative contribution of complex I inhibition, mitochondrial glycerophosphate dehydrogenase and gut-mediated effects is actively disputed between research groups. | An agonist at peroxisome proliferator-activated receptor gamma, a nuclear receptor expressed most highly in adipose tissue. Activating it drives differentiation of new small insulin-sensitive adipocytes, redistributes lipid away from liver and muscle, and lowers circulating free fatty acids, which is how it improves whole-body insulin sensitivity. The same receptor activity drives sodium retention in the kidney, which is the mechanism behind the oedema and heart failure risk, and shifts marrow stem cells toward fat rather than bone, which is the plausible route to the fracture signal. |
| Human studies cited | 3 | 0 |
| Legal status, US | Prescription only; approved for type 2 diabetes | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Metformin and Pioglitazone?
Metformin: The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training. Pioglitazone: An approved diabetes drug with real cardiovascular outcome data in people, and the only compound in the 2026 mouse cohort that shortened female lifespan in the analysis that survived removing an outlier site.
Which has stronger research evidence, Metformin or Pioglitazone?
This database does not grade compounds. It counts what was run in people: 3 of the 4 studies cited on the Metformin profile were human work, against 0 of 1 for Pioglitazone. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Metformin and Pioglitazone FDA-approved?
Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.. Pioglitazone: FDA-approved as Actos for type 2 diabetes. Carries a boxed warning for congestive heart failure. Not approved for any ageing or longevity indication..
Related posts
Blog articles that cover Metformin or Pioglitazone, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.